CAGE1抗体—艾普蒂

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane: Jurkat cell lysate, Primary antibody: P02443(CAGE1 Antibody) at dilution 1/250, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 30 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human prostate cancer tissue using P02443(CAGE1 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The CAGE1 (Cancer Antigen 1) antibody is a tool used to detect the CAGE1 protein, a member of the cancer-testis antigen (CTA) family. CTAs are typically expressed in germ cells but re-emerge in various cancers, making them potential targets for immunotherapy and biomarkers for malignancy. CAGE1. encoded by the *CAGE* gene, is implicated in tumorigenesis, immune evasion, and chemoresistance. It interacts with epigenetic regulators and transcriptional machinery, influencing pathways like PI3K/AKT/mTOR to promote cell proliferation, survival, and metastasis. Overexpression of CAGE1 is observed in melanoma, lung, breast, and gastrointestinal cancers, correlating with poor prognosis.

CAGE1 antibodies are essential in research to study its role in cancer biology, including mechanisms of immune evasion (e.g., suppressing antigen presentation) or therapy resistance. They are used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to assess protein expression, localization, and interactions. Clinically, these antibodies may aid in diagnostic assays or therapeutic development, such as CAR-T or antibody-drug conjugates targeting CAGE1-positive tumors. Challenges include optimizing specificity due to CAGE1's homology with other CTAs and understanding its context-dependent roles across cancer types. Overall, CAGE1 antibodies bridge basic research and translational oncology, offering insights into cancer mechanisms and therapeutic strategies.